January 31, 2025
Ryoncil® Commercial Launch Update and Product Pipeline
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
Pharmaceuticals, Biotechnology and Life Sciences
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
HANOVER, Md, Jan. 30, 2025 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical…
IRVINE, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in…
MISSISSAUGA, Ontario, Jan. 30, 2025 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce…
Diag-Nose.io, a CDL-Seattle graduate, harnesses AI with RhinoMAP™ to redefine respiratory care, securing $2M in oversubscribed fundingSEATTLE, Jan. 30, 2025…
MELBOURNE, Australia and INDIANAPOLIS, Jan. 31, 2025 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company)…
Diag-Nose.io sets new standards in respiratory care with AI and proteomics after a $2M seed funding success, now expanding to…
Diag-Nose.io launches Houston office to advance precise respiratory care using AI and proteomics after a successful $2M seed roundHOUSTON, Jan.…
Diag-Nose.io, a Stanford EENT Innovation graduate, secures $2M in oversubscribed seed funding to revolutionize respiratory care with precise, AI-driven diagnostics…